Astel­las part­ners with In­sil­i­co, Har­vard; Zam­bon gets FDA's fast track sta­tus for lung drug

→ An­oth­er day, an­oth­er In­sil­i­co deal. Weeks af­ter un­veil­ing a tie-up with Ger­many’s Boehringer In­gel­heim — the pro­lif­ic deal­mak­ing pow­ers-that-be at the Hong Kong-based AI start­up have lured yet an­oth­er high pro­file part­ner: Astel­las.

As usu­al, no deal terms were dis­closed. “Astel­las it­self is one of the lead­ers in com­pu­ta­tion­al chem­istry and AI,” chief Alex Zha­voronkov told End­points News via email. “Many Big Phar­ma com­pa­nies that are mak­ing a lot of noise say­ing that they are in­vest­ing in AI of­ten re­quire a lot of work to ed­u­cate them on gen­er­a­tive chem­istry and show the plat­form be­fore clos­ing a deal. But Astel­las has some of the best peo­ple who un­der­stand how things work and have peo­ple we re­spect a lot.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER